Soligenix Inc. (NASDAQ:SNGX) shares surged on Thursday as the company announced positive results from its Phase 2a ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and ...

Soligenix Inc.’s phase IIa study of SGX-945 (dusquetide) for treating oral ulcers in those with Behçet's disease showed biological efficacy in the proof-of-concept study. The positive results ...

According to estimates compiled by Soligenix, as many as 1,000,000 people worldwide live with Behçet’s Disease, with approximately 18,000 known cases in the U.S. and 80,000 in Europe.

There are approximately 18,000 known cases of Behçet's Disease in the U.S. and 80,000 in Europe. There are as many as 1,000,000 people worldwide living with Behçet's Disease.

There are approximately 18,000 known cases of Behçet's Disease in the U.S. and 80,000 in Europe. There are as many as 1,000,000 people worldwide living with Behçet's Disease.

news Dentists’ Rx for Opioids Pose Danger for Drug Interactions ... October 6, 2020 PPI Use and Periodontal Disease: What’s the Link? ... By Diana Ernst, RPh December 13, 2019 ...

A 42-year-old female with aphthouslike ulcerations The woman had multiple aphthouslike ulcers involving her keratinized and nonkeratinized oral mucosa and most often on her dorsal tongue. The ulcers ...

The British Society for Rheumatology and the British Association of Dermatologists developed guidelines for the management of people living with Behçet's disease.

Study results support advancing SGX945 in this difficult to treat orphan disease PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company) ...

Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behcet's Disease 21.02.2025 / 15:04 CET/CEST The issuer is solely responsible for the ...